Search

Your search keyword '"Nagai, Koji"' showing total 29 results
Start Over Author "Nagai, Koji" Publisher wiley-blackwell
29 results on '"Nagai, Koji"'

1. Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.

Author

Shirasugi, Iku, Onishi, Akira, Nishimura, Keisuke, Yamamoto, Wataru, Murakami, Kosaku, Onizawa, Hideo, Maeda, Yuichi, Ebina, Kosuke, Son, Yonsu, Amuro, Hideki, Katayama, Masaki, Hara, Ryota, Nagai, Koji, Hiramatsu, Yuri, Hashimoto, Motomu, Okano, Tadashi, Maeda, Toshihisa, Hayashi, Shinya, Sendo, Sho, and Jinno, Sadao

Subjects
RHEUMATOID arthritis, ANTIRHEUMATIC agents, KINASE inhibitors, INTERLEUKIN-6 receptors, ANKLE joint, PROPORTIONAL hazards models
Abstract

Aim: To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease‐modifying antirheumatic drug or Janus kinase inhibitor. Methods: Patients with RA from a Japanese multicenter observational registry were enrolled. Our definition of large joints included the shoulder, elbow, hip, knee, and ankle joints. Linear mixed‐effects models were used to examine changes in the clinical disease activity index (CDAI) score at Week 24 as the primary outcome, and drug retention rates were compared between patients with and without LJI using Cox proportional hazards models. We examined the potential effect modifications of changes in the CDAI by baseline characteristics. Results: Overall, 2507 treatment courses from 1721 patients were included (LJI, 1744; no LJI, 763). Although LJI was associated with significantly higher changes in CDAI from baseline at Week 24 (difference in change in CDAI: −5.84 [−6.65 to −5.03], p <.001), CDAI was significantly higher in patients with LJI over time. Retention rates were similar in both groups. The association of LJI with changes in disease activity was more prominent in patients with a short disease duration, negative anti‐citrullinated peptide antibodies, and interleukin‐6 receptor inhibitor (IL‐6Ri) use. Conclusion: Although LJI was associated with a greater reduction in disease activity from baseline, higher disease activity at baseline was not offset over time in patients with LJI, demonstrating that LJI is an unfavorable predictor. An early treat‐to‐target strategy using an IL‐6Ri may be beneficial for patients with LJI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single‐center study.

Author

Yoshida, Shuzo, Kotani, Takuya, Kimura, Yuko, Matsumura, Yoko, Yoshikawa, Ayaka, Tokai, Nao, Ozaki, Takuro, Nagai, Koji, Takeuchi, Toru, Makino, Shigeki, and Arawaka, Shigeki

Subjects
RHEUMATOID arthritis, LONGITUDINAL method, DISEASE duration, BIOLOGICAL laboratories, C-reactive protein
Abstract

Aim: To investigate whether remission can be sustained for rheumatoid arthritis (RA) patients after tapering abatacept (ABT). Method: All patients were naïve to biological disease‐modifying anti‐rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints with C‐reactive protein (DAS)28‐CRP). ABT was administrated intravenously (IV) or subcutaneously (SC) for 36 weeks to patients with RA, who had not previously received bDMARDs. As the ABT tapering protocol, ABT was administrated SC at 125 mg every 2 weeks for 12 weeks in patients with remission. RA disease activity was assessed by DAS28‐CRP and ultrasonography. Remission was assessed by defining it as DAS28‐CRP <2.3. Results: Of the 51 patients, 84.3% were women (mean age 68.7 ± 10.2 years, mean disease duration 7.7 ± 10.2 years). Twenty‐nine patients achieved remission and a power Doppler (PD) score ≤1 at each joint at 36 weeks, followed by tapering ABT. Of these patients, 25 sustained DAS28‐CRP remission, and DAS28‐CRP was not significantly elevated (1.62 ± 0.41 to 1.69 ± 0.49) at 48 weeks, but the total PD score was significantly elevated (1.52 ± 1.21 to 2.59 ± 2.81 P = 0.049). Longer disease duration, higher DAS28‐CRP at 24 weeks, and higher total PD score at 24 weeks were predictors of an elevated total PD score after tapering ABT therapy. Conclusion: These findings suggest that ABT tapering is a promising short‐term strategy to sustain remission in patients with RA, and ultrasonography is a useful tool for monitoring disease activity after tapering ABT. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. Cover Picture: Azumamides A-E: Histone Deacetylase Inhibitory Cyclic Tetrapeptides from the Marine Sponge Mycale izuensis / Total Synthesis of Azumamides A and E Z602047 Z602033 (Angew. Chem. Int. Ed. 45/2006).

Author

Nakao, Yoichi, Yoshida, Satoru, Matsunaga, Shigeki, Shindoh, Nobuaki, Terada, Yoh, Nagai, Koji, Yamashita, Jun K., Ganesan, A., van Soest, Rob W. M., Fusetani, Nobuhiro, Izzo, Irene, Maulucci, Nakia, Bifulco, Giuseppe, and De Riccardis, Francesco

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results